Farma

BioBull
BGBIO 18.10.2022 kl 10:28 1348

Jeg håper ikke dette nye viruset «slipper ut», men kommer det til Europa vil nok Bemcentinib ta knekken på dette også.

https://open.substack.com/pub/viralimmunologist/p/lab-in-boston-made-what-could-be?r=1gsxwe&utm_campaign=post&utm_medium=email


https://open.substack.com/pub/viralimmunologist/p/lab-in-boston-made-what-could-be?utm_source=direct&utm_campaign=post&utm_medium=web


I was in shock when a couple of my colleagues directed me to a pre-print article that was posted online on Friday October 14, 2022. Pre-prints are scientific papers that have not yet undergone peer review and they have not been published in a journal. In this case, these nuances are moot. What is far more important is the product that has been described, along with the disclosure of the recipe to make it.

You can find the pre-print article at this link.

Here is the full citation:

Title: “Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron”

Authors: Da-Yuan Chen, Devin Kenney, Chue Vin Chin, Alexander H. Tavares, Nazimuddin Khan, Hasahn L. Conway, GuanQun Liu, Manish C. Choudhary, Hans P. Gertje, Aoife K. O’Connell, Darrell N. Kotton, Alexandra Herrmann, Armin Ensser, John H. Connor, Markus Bosmann, Jonathan Z. Li, Michaela U. Gack, Susan C. Baker, Robert N. Kirchdoerfer, Yachana Kataria, Nicholas A. Crossland, Florian Douam, Mohsan Saeed

bioRxiv 2022.10.13.512134

doi: https://doi.org/10.1101/2022.10.13.512134

Redigert 18.10.2022 kl 10:37

Rapportér innlegg

Vennligst skriv inn kommentar på hva du mener er upassende og trykk send. Dersom kommentar ikke er nødvendig, vennligst trykk send direkte.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.